Dapirolizumab pegol

Biogen navigates Alzheimer's treatment Leqembi launch and pipeline shifts. Key growth drivers include Leqembi and Skyclarys for Friedreich's ataxia. Strategic moves like acquiring HI-Bio and financial stability with strong cash flow and gross margin support Biogen's prospects. Competitive landscape and regulatory challenges in Europe pose risks. Analysts' mixed outlook ranges from $175 to $294, emphasizing Leqembi's success and pipeline developments.

Tonix Pharmaceuticals filed an NDA for TNX-102 SL in fibromyalgia, supported by positive Phase 3 trial results. TNX-801, a vaccine for mpox and smallpox, is in development, with new data showing no spread in immunocompromised animals. Tonix is also developing TNX-1500, a third-generation anti-CD40L antibody for autoimmune diseases and transplant rejection. Financial results show decreased R&D and G&A expenses, with $28.2 million in cash and cash equivalents as of September 30, 2024.

The article discusses the importance of enabling JavaScript for optimal app performance.

Dapirolizumab pegol, a therapy developed by UCB and Biogen, showed significant improvement in controlling disease activity in systemic lupus erythematosus (SLE) patients in a Phase 3 trial. The therapy met its primary goal of achieving a British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response, with 49.5% of patients on dapirolizumab pegol achieving this response compared to 34.6% on placebo. Additionally, patients experienced 50% fewer severe disease flares and were able to reduce corticosteroid doses. The therapy is generally well-tolerated, and the developers plan to further test it in a second Phase 3 trial, PHOENYCS FLY.

Lupus Therapeutics, affiliated with Lupus Research Alliance, is encouraged by the positive Phase 3 PHOENYCS GO data for dapirolizumab pegol (DZP) in treating moderate-to-severe systemic lupus erythematosus (SLE), showing significant improvement in disease activity. UCB and Biogen are initiating a second Phase 3 trial, PHOENYCS FLY, in 2024.

Biogen and UCB detailed Phase III PHOENYCS GO trial results for dapirolizumab pegol, showing a 49.5% response rate vs. 34.6% with standard care, significant in lupus. DZP hit key secondary endpoints, improved disease activity scores, and corticosteroid tapering, with a well-tolerated side effect profile. A second Phase III trial is planned.

Phase 3 PHOENYCS GO study results show dapirolizumab pegol significantly reduces SLE disease activity, with a favorable safety profile.

Dapirolizumab pegol (DZP) met primary endpoint in Phase 3 PHOENYCS GO study, showing significant improvement in SLE disease activity. DZP plus standard of care (SOC) resulted in 50% fewer severe flares and a favorable safety profile compared to SOC alone.

Biogen/UCB’s lupus drug, dapirolizumab pegol, demonstrated consistent efficacy across all endpoints in its first Phase III study, with meaningful improvements over placebo over time. A second Phase III trial is planned for this year.

Lupus Research Alliance announces 33 studies to be presented at ACR Convergence 2024, covering foundational research, clinical trials, and equity in lupus trials, highlighting advancements from bench to bedside.